Suppr超能文献

原位导管癌的检测方法并无治疗意义:一项基于人群的队列研究结果

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

作者信息

Elshof Lotte E, Schaapveld Michael, Rutgers Emiel J, Schmidt Marjanka K, de Munck Linda, van Leeuwen Flora E, Wesseling Jelle

机构信息

Division of Molecular Pathology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

Division of Psychosocial research and Epidemiology, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands.

出版信息

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

Abstract

BACKGROUND

Population screening with mammography has resulted in increased detection of ductal carcinoma in situ (DCIS). The aim of this population-based cohort study was to assess whether the method of detection should be considered when determining prognosis and treatment in women with DCIS.

METHODS

This study includes 7042 women aged 49-75 years, who were surgically treated for primary DCIS between 1989 and 2004 in the Netherlands. We calculated cumulative incidences of ipsilateral and contralateral invasive breast cancer and all-cause mortality among women with screen-detected, interval, or non-screening-related DCIS, and assessed the association between method of detection and these outcomes, using multivariable Cox regression analyses.

RESULTS

Compared with non-screening-related DCIS, women with screen-detected DCIS had a lower risk of developing ipsilateral invasive breast cancer (hazard ratio (HR) = 0.75, 95% CI = 0.59-0.96), but a similar risk of contralateral invasive breast cancer (HR = 0.86, 95% CI = 0.67-1.10). The absolute difference in risk of ipsilateral invasive breast cancer was 1% at 15 years. Screen detection was associated with lower all-cause mortality (HR = 0.85, 95% CI = 0.73-0.98); when we additionally accounted for the occurrence of invasive breast cancer the magnitude of this effect remained similar (HR = 0.86, 95% CI = 0.75-1.00).

CONCLUSIONS

Screen detection was associated with lower risk of ipsilateral invasive breast cancer and all-cause mortality. However, the absolute difference in risk of ipsilateral invasive breast cancer was very low and the lower all-cause mortality associated with screen-detected and interval DCIS might be explained by a healthy-user effect. Therefore, our findings do not justify different treatment strategies for women with screen-detected, interval, or non-screening-related DCIS.

摘要

背景

乳腺钼靶筛查已使导管原位癌(DCIS)的检出率增加。这项基于人群的队列研究旨在评估在确定DCIS女性的预后和治疗时,是否应考虑检测方法。

方法

本研究纳入了1989年至2004年在荷兰因原发性DCIS接受手术治疗的7042名49 - 75岁女性。我们计算了筛查发现、间期或与筛查无关的DCIS女性同侧和对侧浸润性乳腺癌的累积发病率以及全因死亡率,并使用多变量Cox回归分析评估检测方法与这些结局之间的关联。

结果

与非筛查相关的DCIS相比,筛查发现DCIS的女性发生同侧浸润性乳腺癌的风险较低(风险比(HR)= 0.75,95%置信区间(CI)= 0.59 - 0.96),但对侧浸润性乳腺癌的风险相似(HR = 0.86,95% CI = 0.67 - 1.10)。15年时同侧浸润性乳腺癌风险的绝对差异为1%。筛查发现与较低的全因死亡率相关(HR = 0.85,95% CI = 0.73 - 0.98);当我们进一步考虑浸润性乳腺癌的发生情况时,这种效应的大小仍然相似(HR = 0.86,95% CI = 0.75 - 1.00)。

结论

筛查发现与较低的同侧浸润性乳腺癌风险和全因死亡率相关。然而,同侧浸润性乳腺癌风险的绝对差异非常小,且筛查发现和间期DCIS相关的较低全因死亡率可能由健康使用者效应来解释。因此,我们的研究结果并不支持对筛查发现、间期或与筛查无关的DCIS女性采取不同的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d17/5343406/2f1b1e3cb62d/13058_2017_819_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验